449 related articles for article (PubMed ID: 29352109)
21. CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA.
Flynn R; Hutchinson T; Murphy KM; Ware CF; Croft M; Salek-Ardakani S
PLoS One; 2013; 8(10):e77991. PubMed ID: 24205056
[TBL] [Abstract][Full Text] [Related]
22. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
[TBL] [Abstract][Full Text] [Related]
23. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
24. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients.
Posselt AM; Vincenti F; Bedolli M; Lantz M; Roberts JP; Hirose R
Transplantation; 2003 Jul; 76(1):190-5. PubMed ID: 12865808
[TBL] [Abstract][Full Text] [Related]
25. The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.
Shang Y; Guo G; Cui Q; Li J; Ruan Z; Chen Y
Inflammation; 2012 Jun; 35(3):1102-12. PubMed ID: 22179929
[TBL] [Abstract][Full Text] [Related]
26. Clinical Significance of BTLA and HVEM Expression on Circulating CD4
Song HF; Chen XJ; Tang PJ; Xu P; Huang ZY; Wang XF
Viral Immunol; 2022 May; 35(4):291-302. PubMed ID: 35196150
[TBL] [Abstract][Full Text] [Related]
27. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
[TBL] [Abstract][Full Text] [Related]
28. B- and T-lymphocyte attenuator targeting protects against the acute phase of graft versus host reaction by inhibiting donor anti-host cytotoxicity.
del Rio ML; Kurtz J; Perez-Martinez C; Ghosh A; Perez-Simon JA; Rodriguez-Barbosa JI
Transplantation; 2011 Nov; 92(10):1085-93. PubMed ID: 21978997
[TBL] [Abstract][Full Text] [Related]
29. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.
Zhang M; Howard K; Winters A; Steavenson S; Anderson S; Smelt S; Doellgast G; Sheelo C; Stevens J; Kim H; Hamburger A; Sein A; Caughey DJ; Lee F; Hsu H; Siu G; Byrne FR
Clin Exp Immunol; 2011 Jan; 163(1):77-87. PubMed ID: 21078085
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
[TBL] [Abstract][Full Text] [Related]
32. A crucial role for HVEM and BTLA in preventing intestinal inflammation.
Steinberg MW; Turovskaya O; Shaikh RB; Kim G; McCole DF; Pfeffer K; Murphy KM; Ware CF; Kronenberg M
J Exp Med; 2008 Jun; 205(6):1463-76. PubMed ID: 18519647
[TBL] [Abstract][Full Text] [Related]
33. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
Front Immunol; 2018; 9():2611. PubMed ID: 30483269
[TBL] [Abstract][Full Text] [Related]
34. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
35. Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.
Shrestha R; Garrett-Thomson SC; Liu W; Almo SC; Fiser A
Structure; 2020 Nov; 28(11):1197-1205.e2. PubMed ID: 32795404
[TBL] [Abstract][Full Text] [Related]
36. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells.
De Trez C; Schneider K; Potter K; Droin N; Fulton J; Norris PS; Ha SW; Fu YX; Murphy T; Murphy KM; Pfeffer K; Benedict CA; Ware CF
J Immunol; 2008 Jan; 180(1):238-48. PubMed ID: 18097025
[TBL] [Abstract][Full Text] [Related]
37. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.
Sedy JR; Gavrieli M; Potter KG; Hurchla MA; Lindsley RC; Hildner K; Scheu S; Pfeffer K; Ware CF; Murphy TL; Murphy KM
Nat Immunol; 2005 Jan; 6(1):90-8. PubMed ID: 15568026
[TBL] [Abstract][Full Text] [Related]
38. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
[TBL] [Abstract][Full Text] [Related]
39. Roles of BTLA in Immunity and Immune Disorders.
Ning Z; Liu K; Xiong H
Front Immunol; 2021; 12():654960. PubMed ID: 33859648
[TBL] [Abstract][Full Text] [Related]
40. The Absence of Lymphotoxin-α, a Herpesvirus Entry Mediator (HVEM) Ligand, Affects Herpes Simplex Virus 1 Infection
Wang S; Hirose S; Ghiasi H
J Virol; 2019 Aug; 93(16):. PubMed ID: 31142672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
